FDA-cleared profile

Automatic Anatomy Recognition (AAR)

Quantitative Radiology Solutions, LLC · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: Automatic Anatomy Recognition is cloud software that generates initial organ-at-risk contours from adult noncontrast CT of the head, neck, and thorax for transfer to a third-party radiation treatment-planning system; it has no contour-editing function and does not calculate dose or optimize plans.

Clinical role
Automatic initial organ-at-risk contouring independent of treatment modality, delivery method, or treatment intent.
Images and patients
Radiotherapy Planning Imaging · Head/Neck/Chest
Key limitation
Keep in mind: AAR is not for use on patients below 18 years of age, is intended only for head and neck and thoracic body regions, does not provide the capability to modify contours, and relies on third-party treatment planning systems to display and edit the contours.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatic Anatomy Recognition is cloud software that generates initial organ-at-risk contours from adult noncontrast CT of the head, neck, and thorax for transfer to a third-party radiation treatment-planning system; it has no contour-editing function and does not calculate dose or optimize plans.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Head/Neck/Chest Input: Adult DICOM 3.0 noncontrast CT studies of head and neck or thorax.
  • Who uses it?Intended users: Technicians and trained physicians involved in radiation-therapy planning.
  • What does the software produce?Output: DICOM contours for display and editing in a third-party treatment-planning system.
  • What is its most important limitation?Key limitation: AAR is not for use on patients below 18 years of age, is intended only for head and neck and thoracic body regions, does not provide the capability to modify contours, and relies on third-party treatment planning systems to display and edit the contours.

Clinical takeaway. Clinical role: Automatic Anatomy Recognition is cloud software that generates initial organ-at-risk contours from adult noncontrast CT of the head, neck, and thorax for transfer to a third-party radiation treatment-planning system; it has no contour-editing function and does not calculate dose or optimize plans.

Evidence takeaway. Evidence from the reviewed source record: K203610 reports unit, integration, system, and segmentation-performance testing using Dice and 95% Hausdorff distance but no public numerical results or clinical study. Developer-affiliated peer-reviewed AAR research provides broader algorithm context across 216 planning CTs and more than 2,600 objects, not exact-release clinical validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatic Anatomy Recognition is cloud software that generates initial organ-at-risk contours from adult noncontrast CT of the head, neck, and thorax for transfer to a third-party radiation treatment-planning system; it has no contour-editing function and does not calculate dose or optimize plans.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Automatic initial organ-at-risk contouring independent of treatment modality, delivery method, or treatment intent.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Adult DICOM 3.0 noncontrast CT studies of head and neck or thorax.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
DICOM contours for display and editing in a third-party treatment-planning system.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Radiation-oncology departments using DICOM-compliant CT and third-party treatment-planning systems.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Technicians and trained physicians involved in radiation-therapy planning.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
AAR is not for use on patients below 18 years of age, is intended only for head and neck and thoracic body regions, does not provide the capability to modify contours, and relies on third-party treatment planning systems to display and edit the contours.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet states the age, anatomic, contour-editing, and third-party-system boundaries but does not state the dossier's additional dose, registration, or plan-optimization exclusions.

Evidence summary
K203610 reports unit, integration, system, and segmentation-performance testing using Dice and 95% Hausdorff distance but no public numerical results or clinical study. Developer-affiliated peer-reviewed AAR research provides broader algorithm context across 216 planning CTs and more than 2,600 objects, not exact-release clinical validation.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K203610 reports unit, integration, system, and segmentation-performance testing using Dice and 95% Hausdorff distance but no public numerical results or clinical study. Developer-affiliated peer-reviewed AAR research provides broader algorithm context across 216 planning CTs and more than 2,600 objects, not exact-release clinical validation.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K203610 FDA performance package for Automatic Anatomy Recognition (AAR)

  • DesignManufacturer nonclinical software and segmentation verification
  • PopulationAdult noncontrast head, neck, and thoracic radiotherapy-planning CT
  • Scopeexact submission
  • Tested versionAutomatic Anatomy Recognition release cleared in K203610
  • IndependenceSponsor or vendor study

K203610

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Automatic anatomy recognition in radiotherapy planning CT

  • DesignDeveloper-affiliated retrospective algorithm evaluation
  • Population216 radiotherapy planning CT examinations with more than 2,600 delineated objects
  • Scopeproduct family
  • Tested versionAAR research implementation; exact K203610 build not established
  • Samplen=216
  • IndependenceIndependent study

PMC6122857

Supports algorithm-family context only; artifact burden, anatomy, and contour definition affect performance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K203610 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult DICOM 3.0 noncontrast CT studies of head and neck or thorax.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K203610: Automatic Anatomy Recognition (AAR)

  2. Routing

    Source context, not route validation: Cloud software on Linux with DICOM 3.0 CT input and TPS output; validate transfer, structure naming, supported anatomy, noncontrast protocols, editing, approval, and failed-case quarantine.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K203610: Automatic Anatomy Recognition (AAR)

  3. AI processing

    Source context, not route validation: Software-only cloud platform with Linux processing and third-party treatment-planning integration.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K203610: Automatic Anatomy Recognition (AAR)

  4. Returned objects

    Source context, not route validation: DICOM contours for display and editing in a third-party treatment-planning system.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K203610: Automatic Anatomy Recognition (AAR)

  5. Viewer/worklist/report

    Unresolved route: DICOM contours for display and editing in a third-party treatment-planning system.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K203610: Automatic Anatomy Recognition (AAR)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software-only cloud platform with Linux processing and third-party treatment-planning integration.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Cloud software on Linux with DICOM 3.0 CT input and TPS output; validate transfer, structure naming, supported anatomy, noncontrast protocols, editing, approval, and failed-case quarantine.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only technicians and trained physicians involved in radiation-therapy planning. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Not for patients younger than 18, abdomen or pelvis, contrast CT, dose calculation, registration, plan optimization, or contour editing. A third-party TPS must display and edit every contour.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K203610 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Cloud software on Linux with DICOM 3.0 CT input and TPS output; validate transfer, structure naming, supported anatomy, noncontrast protocols, editing, approval, and failed-case quarantine.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Not for patients younger than 18, abdomen or pelvis, contrast CT, dose calculation, registration, plan optimization, or contour editing. A third-party TPS must display and edit every contour.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Not for patients younger than 18, abdomen or pelvis, contrast CT, dose calculation, registration, plan optimization, or contour editing. A third-party TPS must display and edit every contour.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K203610
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Head/Neck/Chest
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-04-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, peer reviewed publication, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA K203610: Automatic Anatomy Recognition (AAR)

    U.S. Food and Drug Administration - Published 2021-04-20 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Automatic anatomy recognition in radiation-therapy planning CT

    Medical Physics - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring

Research history

  1. K203610 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253050

RadOncAI

Informai

An AI-guided planning tool that predicts radiation dose information for adult head-and-neck treatment planning.

Modality
Radiotherapy Planning Imaging
Anatomy
Head and neck
Decision
2026-06-18
FDA-cleared K252190

DeepBT Detector-Plus

Aitewan Biomedical Technology, Inc.

Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Decision
2026-04-10
FDA-cleared K252548

AI-Rad Companion Organs RT

Siemens Healthcare GmbH

Authorized purpose: AI-Rad Companion Organs RT VA70 automatically contours predefined structures, including known diagnosed brain metastases, on DICOM CT and MR images for radiation therapy planning; qualified users must review, edit and accept contours in suitable planning or contouring software, and the device is not intended for diagnosis.

Modality
Radiotherapy Planning Imaging
Anatomy
Head/neck, thorax, abdomen, pelvis; MR brain and male pelvis
Decision
2026-04-10
FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history